Shopping Cart 0
Cart Subtotal
AED 0

Colorectal Cancer - Pipeline Review, H1 2018

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
AED 9175

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
AED 18350

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
AED 27525

Details

Colorectal Cancer-Pipeline Review, H1 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Colorectal Cancer-Pipeline Review, H1 2018, provides an overview of the Colorectal Cancer (Oncology) pipeline landscape.

Colorectal cancer is a cancer that starts in the colon or the rectum. Colorectal cancers begin as a growth called a polyp on the inner lining of the colon or rectum. Symptoms include abdominal pain and tenderness in the lower abdomen, blood in the stool, diarrhea, constipation, change in bowel habits, narrow stools and weight loss with no known reason. Risk factors include smoking, heavy alcohol use, inflammatory bowel disease (IBD) and family history. Treatment includes surgery, radiation therapy and chemotherapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Colorectal Cancer-Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Colorectal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Colorectal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Colorectal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 1, 27, 132, 157, 16, 185, 32 and 14 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 1, 23, 9, 1, 30 and 3 molecules, respectively.

Colorectal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Colorectal Cancer (Oncology).

- The pipeline guide reviews pipeline therapeutics for Colorectal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Colorectal Cancer (Oncology) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Colorectal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Colorectal Cancer (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Colorectal Cancer (Oncology).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Colorectal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 2

Introduction 12

Colorectal Cancer-Overview 13

Colorectal Cancer-Therapeutics Development 14

Colorectal Cancer-Therapeutics Assessment 76

Colorectal Cancer-Companies Involved in Therapeutics Development 106

Colorectal Cancer-Drug Profiles 226

Colorectal Cancer-Dormant Projects 2137

Colorectal Cancer-Discontinued Products 2160

Colorectal Cancer-Product Development Milestones 2165

Appendix 2176


List Of Figure

List of Figures

Number of Products under Development for Colorectal Cancer, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Top 10 Routes of Administration, H1 2018

Number of Products by Stage and Top 10 Routes of Administration, H1 2018

Number of Products by Top 10 Molecule Types, H1 2018

Number of Products by Stage and Top 10 Molecule Types, H1 2018


List Of Table

List of Tables

Number of Products under Development for Colorectal Cancer, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Colorectal Cancer-Pipeline by 3-V Biosciences Inc, H1 2018

Colorectal Cancer-Pipeline by 3SBio Inc, H1 2018

Colorectal Cancer-Pipeline by 4SC AG, H1 2018

Colorectal Cancer-Pipeline by AB Science SA, H1 2018

Colorectal Cancer-Pipeline by AbbVie Inc, H1 2018

Colorectal Cancer-Pipeline by AbGenomics International Inc, H1 2018

Colorectal Cancer-Pipeline by Abpro, H1 2018

Colorectal Cancer-Pipeline by Aclaris Therapeutics Inc, H1 2018

Colorectal Cancer-Pipeline by Adamed Sp z oo, H1 2018

Colorectal Cancer-Pipeline by Aduro BioTech Inc, H1 2018

Colorectal Cancer-Pipeline by Advenchen Laboratories LLC, H1 2018

Colorectal Cancer-Pipeline by AlfaSigma SpA, H1 2018

Colorectal Cancer-Pipeline by Alligator Bioscience AB, H1 2018

Colorectal Cancer-Pipeline by Allinky Biopharma, H1 2018

Colorectal Cancer-Pipeline by Amarin Corp Plc, H1 2018

Colorectal Cancer-Pipeline by amcure GmbH, H1 2018

Colorectal Cancer-Pipeline by Amgen Inc, H1 2018

Colorectal Cancer-Pipeline by Antibe Therapeutics Inc, H1 2018

Colorectal Cancer-Pipeline by APEIRON Biologics AG, H1 2018

Colorectal Cancer-Pipeline by Apexigen Inc, H1 2018

Colorectal Cancer-Pipeline by Aphios Corp, H1 2018

Colorectal Cancer-Pipeline by Aposense Ltd, H1 2018

Colorectal Cancer-Pipeline by Arcus Biosciences Inc, H1 2018

Colorectal Cancer-Pipeline by ARMO Biosciences Inc, H1 2018

Colorectal Cancer-Pipeline by ArQule Inc, H1 2018

Colorectal Cancer-Pipeline by Array BioPharma Inc, H1 2018

Colorectal Cancer-Pipeline by Asana BioSciences LLC, H1 2018

Colorectal Cancer-Pipeline by Ascelia Pharma AB, H1 2018

Colorectal Cancer-Pipeline by Aslan Pharmaceuticals Pte Ltd, H1 2018

Colorectal Cancer-Pipeline by Astellas Pharma Inc, H1 2018

Colorectal Cancer-Pipeline by Astex Pharmaceuticals Inc, H1 2018

Colorectal Cancer-Pipeline by AstraZeneca Plc, H1 2018

Colorectal Cancer-Pipeline by Aurigene Discovery Technologies Ltd, H1 2018

Colorectal Cancer-Pipeline by Aurobindo Pharma Ltd, H1 2018

Colorectal Cancer-Pipeline by AVEO Pharmaceuticals Inc, H1 2018

Colorectal Cancer-Pipeline by B Cell Design SAS, H1 2018

Colorectal Cancer-Pipeline by Basilea Pharmaceutica Ltd, H1 2018

Colorectal Cancer-Pipeline by Bavarian Nordic A/S, H1 2018

Colorectal Cancer-Pipeline by Bayer AG, H1 2018

Colorectal Cancer-Pipeline by BeiGene Ltd, H1 2018

Colorectal Cancer-Pipeline by Beijing Hanmi Pharmaceutical Co Ltd, H1 2018

Colorectal Cancer-Pipeline by BeyondSpring Pharmaceuticals Inc, H1 2018

Colorectal Cancer-Pipeline by Biocon Ltd, H1 2018

Colorectal Cancer-Pipeline by Bionomics Ltd, H1 2018

Colorectal Cancer-Pipeline by Bionovis SA, H1 2018

Colorectal Cancer-Pipeline by Biotecnol Ltd, H1 2018

Colorectal Cancer-Pipeline by Biothera Pharmaceutical Inc, H1 2018

Colorectal Cancer-Pipeline by Boehringer Ingelheim GmbH, H1 2018

Colorectal Cancer-Pipeline by Boston Biomedical Inc, H1 2018

Colorectal Cancer-Pipeline by Bristol-Myers Squibb Co, H1 2018

Colorectal Cancer-Pipeline by Calithera Biosciences Inc, H1 2018

Colorectal Cancer-Pipeline by Cancer Prevention Pharmaceuticals Inc, H1 2018

Colorectal Cancer-Pipeline by Cancer Research Technology Ltd, H1 2018

Colorectal Cancer-Pipeline by Cantargia AB, H1 2018

Colorectal Cancer-Pipeline by Carna Biosciences Inc, H1 2018

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Colorectal Cancer Therapeutic Products under Development, Key Players in Colorectal Cancer Therapeutics, Colorectal Cancer Pipeline Overview, Colorectal Cancer Pipeline, Colorectal Cancer Pipeline Assessment


Companies

3-V Biosciences Inc

3SBio Inc

4SC AG

AB Science SA

AbbVie Inc

AbGenomics International Inc

Abpro

Aclaris Therapeutics Inc

Adamed Sp z oo

Aduro BioTech Inc

Advenchen Laboratories LLC

AlfaSigma SpA

Alligator Bioscience AB

Allinky Biopharma

Amarin Corp Plc

amcure GmbH

Amgen Inc

Antibe Therapeutics Inc

APEIRON Biologics AG

Apexigen Inc

Aphios Corp

Aposense Ltd

Arcus Biosciences Inc

ARMO Biosciences Inc

ArQule Inc

Array BioPharma Inc

Asana BioSciences LLC

Ascelia Pharma AB

Aslan Pharmaceuticals Pte Ltd

Astellas Pharma Inc

Astex Pharmaceuticals Inc

AstraZeneca Plc

Aurigene Discovery Technologies Ltd

Aurobindo Pharma Ltd

AVEO Pharmaceuticals Inc

B Cell Design SAS

Basilea Pharmaceutica Ltd

Bavarian Nordic A/S

Bayer AG

BeiGene Ltd

Beijing Hanmi Pharmaceutical Co Ltd

BeyondSpring Pharmaceuticals Inc

Biocon Ltd

Bionomics Ltd

Bionovis SA

Biotecnol Ltd

Biothera Pharmaceutical Inc

Boehringer Ingelheim GmbH

Boston Biomedical Inc

Bristol-Myers Squibb Co

Calithera Biosciences Inc

Cancer Prevention Pharmaceuticals Inc

Cancer Research Technology Ltd

Cantargia AB

Carna Biosciences Inc

CaroGen Corp

CBT Pharmaceuticals Inc

CCRP Therapeutics GmbH

Celgene Corp

Celldex Therapeutics Inc

Cellectar Biosciences Inc

Celleron Therapeutics Ltd

Cellestia Biotech AG

Cellix Bio Pvt Ltd

Celltrion Inc

Celyad SA

Checkmate Pharmaceuticals Inc

Chipscreen Biosciences Ltd

ChoDang Pharm Co Ltd

Chong Kun Dang Pharmaceutical Corp

Cinnagen Co

Cleveland BioLabs Inc

COARE Biotechnology Inc

Coherus BioSciences Inc

Compugen Ltd

Conatus Pharmaceuticals Inc

Corvus Pharmaceuticals Inc

Cotinga Pharmaceuticals Inc

CrystalGenomics Inc

Daiichi Sankyo Co Ltd

DanDrit Biotech A/S

Deciphera Pharmaceuticals LLC

Dr. Reddy's Laboratories Ltd

eFFECTOR Therapeutics Inc

Eisai Co Ltd

Eli Lilly and Co

Endor Nanotechnologies SL

EntreChem SL

Enzene Biosciences Ltd

Enzo Biochem Inc

EpiThany Inc

Etubics Corp

Exelixis Inc

Exicure Inc

F-star Biotechnology Ltd

F. Hoffmann-La Roche Ltd

Fate Therapeutics Inc

Formation Biologics Inc

Formosa Laboratories Inc

Forty Seven Inc

Fresenius SE & Co KGaA

Fujifilm Holdings Corporation

Fusion Antibodies Ltd

GamaMabs Pharma SA

GC Pharma

Gene Techno Science Co Ltd

Genentech Inc

Genmab A/S

Genoscience Pharma

Genzyme Corp

Gilead Sciences Inc

GlaxoSmithKline Plc

Glenmark Pharmaceuticals Ltd

Glycostem Therapeutics BV

Glycotope GmbH

Handok Inc

Hanmi Pharmaceuticals Co Ltd

Harbin Gloria Pharmaceuticals Co Ltd

Heat Biologics Inc

Heidelberg Pharma AG

Hemispherx Biopharma Inc

Hercules Pharmaceuticals BV

Humanigen Inc

Hutchison MediPharma Ltd

iDD biotech SAS

Ideaya Biosciences Inc

Idera Pharmaceuticals Inc

Ignyta Inc

Ildong Pharmaceutical Co Ltd

Immodulon Therapeutics Ltd

Immunomedics Inc

Immunovative Therapies Ltd

Incanthera Ltd

Incyte Corp

Innate Pharma SA

Innovent Biologics Inc

Inovio Pharmaceuticals Inc

Interprotein Corp

Intezyne Technologies Inc

Ipsen SA

Isofol Medical AB

Jeil Pharmaceutical Co Ltd

JHL Biotech Inc

Jiangsu Hengrui Medicine Co Ltd

Johnson & Johnson

Karyopharm Therapeutics Inc

Kazia Therapeutics Ltd

Kura Oncology Inc

Laboratorio ELEA SACIF y A

LipoMedix Pharmaceutical Inc

Loxo Oncology Inc

Luye Pharma Group Ltd

Mabion SA

mAbxience SA

MacroGenics Inc

Mantis Therapeutics BV

Marina Biotech Inc

Medesis Pharma SA

MediaPharma SRL

MediciNova Inc

MedImmune LLC

Medivir AB

MELEMA Pharma GmbH

Merck & Co Inc

Merck KGaA

Merus NV

MetaMax Ltd

Millennium Pharmaceuticals Inc

Mirati Therapeutics Inc

Moderna Therapeutics Inc

Molecular Partners AG

Molecular Templates Inc

Mologen AG

Morphotek Inc

Multimmune GmbH

Mycenax Biotech Inc

NantKwest Inc

Natco Pharma Ltd

NatureWise Biotech & Medicals Corp

Nektar Therapeutics

Neovacs SA

Nerviano Medical Sciences Srl

Nippon Kayaku Co Ltd

NormOxys Inc

Northwest Biotherapeutics Inc

Novartis AG

Noxxon Pharma AG

NuCana Plc

OBI Pharma Inc

Omnitura Therapeutics Inc

Oncology Research International Ltd

Oncolytics Biotech Inc

OncoMed Pharmaceuticals Inc

Onconova Therapeutics Inc

Ono Pharmaceutical Co Ltd

Otsuka Holdings Co Ltd

Oxford BioTherapeutics Ltd

PDS Biotechnology Corp

Pfizer Inc

Pharma Mar SA

PharmAbcine Inc

Pivotal BioSciences Inc

PlantForm Corp

Plexxikon Inc

Polaris Pharmaceuticals Inc

Precision Biologics Inc

Propanc Biopharma Inc

Protheragen Inc

Provectus Biopharmaceuticals Inc

PsiOxus Therapeutics Ltd

Puma Biotechnology Inc

Puretech Health plc

R Pharm

Rafael Pharmaceuticals Inc

RedHill Biopharma Ltd

Redx Pharma Plc

Regeneron Pharmaceuticals Inc

Rexahn Pharmaceuticals Inc

Rgenix Inc

Rhizen Pharmaceuticals SA

Richter Gedeon Nyrt

Samumed LLC

Sanofi

Scancell Holdings Plc

Seattle Genetics Inc

Second Genome Inc

Selvita SA

Shanghai Henlius Biotech Co Ltd

Siamab Therapeutics Inc

Sichuan Kelun Pharmaceutical Co Ltd

Sierra Oncology Inc

Sillajen Biotherapeutics

Simcere Pharmaceutical Group

Sino Biopharmaceutical Ltd

Sorrento Therapeutics Inc

ST Pharm Co., Ltd.

Steba Biotech SA

Sublimity Therapeutics Ltd

Sumitomo Dainippon Pharma Co Ltd

Sun Pharma Advanced Research Company Ltd

SuviCa Inc

Symphogen A/S

Syndax Pharmaceuticals Inc

SynDevRx Inc

Synermore Biologics Co Ltd

Taiho Pharmaceutical Co Ltd

TaiwanJ Pharmaceuticals Co Ltd

Takeda Pharmaceutical Co Ltd

Targovax ASA

Tarrex Biopharma Ltd

Tarveda Therapeutics Inc

Theralase Technologies Inc

Tocagen Inc

Tolero Pharmaceuticals Inc

TRACON Pharmaceuticals Inc

Trovagene Inc

United BioPharma Inc

Vaccinex Inc

VasGene Therapeutics Inc

Vaximm AG

Vincogen Corp

Vitality Biopharma Inc

WntResearch AB

Wuhan YZY Biopharma Co Ltd

XBiotech Inc

Xencor Inc

XuanZhu Pharma Co Ltd

Zelluna Immunotherapy AS

Zymeworks Inc

Company Profile

Company Profile Title

Colorectal Cancer-Pipeline Review, H1 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Colorectal Cancer-Pipeline Review, H1 2018, provides an overview of the Colorectal Cancer (Oncology) pipeline landscape.

Colorectal cancer is a cancer that starts in the colon or the rectum. Colorectal cancers begin as a growth called a polyp on the inner lining of the colon or rectum. Symptoms include abdominal pain and tenderness in the lower abdomen, blood in the stool, diarrhea, constipation, change in bowel habits, narrow stools and weight loss with no known reason. Risk factors include smoking, heavy alcohol use, inflammatory bowel disease (IBD) and family history. Treatment includes surgery, radiation therapy and chemotherapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Colorectal Cancer-Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Colorectal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Colorectal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Colorectal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 1, 27, 132, 157, 16, 185, 32 and 14 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 1, 23, 9, 1, 30 and 3 molecules, respectively.

Colorectal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Colorectal Cancer (Oncology).

- The pipeline guide reviews pipeline therapeutics for Colorectal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Colorectal Cancer (Oncology) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Colorectal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Colorectal Cancer (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Colorectal Cancer (Oncology).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Colorectal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Scope

Table of Contents

Table of Contents 2

Introduction 12

Colorectal Cancer-Overview 13

Colorectal Cancer-Therapeutics Development 14

Colorectal Cancer-Therapeutics Assessment 76

Colorectal Cancer-Companies Involved in Therapeutics Development 106

Colorectal Cancer-Drug Profiles 226

Colorectal Cancer-Dormant Projects 2137

Colorectal Cancer-Discontinued Products 2160

Colorectal Cancer-Product Development Milestones 2165

Appendix 2176


List Of Figure

List of Figures

Number of Products under Development for Colorectal Cancer, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Top 10 Routes of Administration, H1 2018

Number of Products by Stage and Top 10 Routes of Administration, H1 2018

Number of Products by Top 10 Molecule Types, H1 2018

Number of Products by Stage and Top 10 Molecule Types, H1 2018


List Of Table

List of Tables

Number of Products under Development for Colorectal Cancer, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Colorectal Cancer-Pipeline by 3-V Biosciences Inc, H1 2018

Colorectal Cancer-Pipeline by 3SBio Inc, H1 2018

Colorectal Cancer-Pipeline by 4SC AG, H1 2018

Colorectal Cancer-Pipeline by AB Science SA, H1 2018

Colorectal Cancer-Pipeline by AbbVie Inc, H1 2018

Colorectal Cancer-Pipeline by AbGenomics International Inc, H1 2018

Colorectal Cancer-Pipeline by Abpro, H1 2018

Colorectal Cancer-Pipeline by Aclaris Therapeutics Inc, H1 2018

Colorectal Cancer-Pipeline by Adamed Sp z oo, H1 2018

Colorectal Cancer-Pipeline by Aduro BioTech Inc, H1 2018

Colorectal Cancer-Pipeline by Advenchen Laboratories LLC, H1 2018

Colorectal Cancer-Pipeline by AlfaSigma SpA, H1 2018

Colorectal Cancer-Pipeline by Alligator Bioscience AB, H1 2018

Colorectal Cancer-Pipeline by Allinky Biopharma, H1 2018

Colorectal Cancer-Pipeline by Amarin Corp Plc, H1 2018

Colorectal Cancer-Pipeline by amcure GmbH, H1 2018

Colorectal Cancer-Pipeline by Amgen Inc, H1 2018

Colorectal Cancer-Pipeline by Antibe Therapeutics Inc, H1 2018

Colorectal Cancer-Pipeline by APEIRON Biologics AG, H1 2018

Colorectal Cancer-Pipeline by Apexigen Inc, H1 2018

Colorectal Cancer-Pipeline by Aphios Corp, H1 2018

Colorectal Cancer-Pipeline by Aposense Ltd, H1 2018

Colorectal Cancer-Pipeline by Arcus Biosciences Inc, H1 2018

Colorectal Cancer-Pipeline by ARMO Biosciences Inc, H1 2018

Colorectal Cancer-Pipeline by ArQule Inc, H1 2018

Colorectal Cancer-Pipeline by Array BioPharma Inc, H1 2018

Colorectal Cancer-Pipeline by Asana BioSciences LLC, H1 2018

Colorectal Cancer-Pipeline by Ascelia Pharma AB, H1 2018

Colorectal Cancer-Pipeline by Aslan Pharmaceuticals Pte Ltd, H1 2018

Colorectal Cancer-Pipeline by Astellas Pharma Inc, H1 2018

Colorectal Cancer-Pipeline by Astex Pharmaceuticals Inc, H1 2018

Colorectal Cancer-Pipeline by AstraZeneca Plc, H1 2018

Colorectal Cancer-Pipeline by Aurigene Discovery Technologies Ltd, H1 2018

Colorectal Cancer-Pipeline by Aurobindo Pharma Ltd, H1 2018

Colorectal Cancer-Pipeline by AVEO Pharmaceuticals Inc, H1 2018

Colorectal Cancer-Pipeline by B Cell Design SAS, H1 2018

Colorectal Cancer-Pipeline by Basilea Pharmaceutica Ltd, H1 2018

Colorectal Cancer-Pipeline by Bavarian Nordic A/S, H1 2018

Colorectal Cancer-Pipeline by Bayer AG, H1 2018

Colorectal Cancer-Pipeline by BeiGene Ltd, H1 2018

Colorectal Cancer-Pipeline by Beijing Hanmi Pharmaceutical Co Ltd, H1 2018

Colorectal Cancer-Pipeline by BeyondSpring Pharmaceuticals Inc, H1 2018

Colorectal Cancer-Pipeline by Biocon Ltd, H1 2018

Colorectal Cancer-Pipeline by Bionomics Ltd, H1 2018

Colorectal Cancer-Pipeline by Bionovis SA, H1 2018

Colorectal Cancer-Pipeline by Biotecnol Ltd, H1 2018

Colorectal Cancer-Pipeline by Biothera Pharmaceutical Inc, H1 2018

Colorectal Cancer-Pipeline by Boehringer Ingelheim GmbH, H1 2018

Colorectal Cancer-Pipeline by Boston Biomedical Inc, H1 2018

Colorectal Cancer-Pipeline by Bristol-Myers Squibb Co, H1 2018

Colorectal Cancer-Pipeline by Calithera Biosciences Inc, H1 2018

Colorectal Cancer-Pipeline by Cancer Prevention Pharmaceuticals Inc, H1 2018

Colorectal Cancer-Pipeline by Cancer Research Technology Ltd, H1 2018

Colorectal Cancer-Pipeline by Cantargia AB, H1 2018

Colorectal Cancer-Pipeline by Carna Biosciences Inc, H1 2018

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Colorectal Cancer Therapeutic Products under Development, Key Players in Colorectal Cancer Therapeutics, Colorectal Cancer Pipeline Overview, Colorectal Cancer Pipeline, Colorectal Cancer Pipeline Assessment


Companies

3-V Biosciences Inc

3SBio Inc

4SC AG

AB Science SA

AbbVie Inc

AbGenomics International Inc

Abpro

Aclaris Therapeutics Inc

Adamed Sp z oo

Aduro BioTech Inc

Advenchen Laboratories LLC

AlfaSigma SpA

Alligator Bioscience AB

Allinky Biopharma

Amarin Corp Plc

amcure GmbH

Amgen Inc

Antibe Therapeutics Inc

APEIRON Biologics AG

Apexigen Inc

Aphios Corp

Aposense Ltd

Arcus Biosciences Inc

ARMO Biosciences Inc

ArQule Inc

Array BioPharma Inc

Asana BioSciences LLC

Ascelia Pharma AB

Aslan Pharmaceuticals Pte Ltd

Astellas Pharma Inc

Astex Pharmaceuticals Inc

AstraZeneca Plc

Aurigene Discovery Technologies Ltd

Aurobindo Pharma Ltd

AVEO Pharmaceuticals Inc

B Cell Design SAS

Basilea Pharmaceutica Ltd

Bavarian Nordic A/S

Bayer AG

BeiGene Ltd

Beijing Hanmi Pharmaceutical Co Ltd

BeyondSpring Pharmaceuticals Inc

Biocon Ltd

Bionomics Ltd

Bionovis SA

Biotecnol Ltd

Biothera Pharmaceutical Inc

Boehringer Ingelheim GmbH

Boston Biomedical Inc

Bristol-Myers Squibb Co

Calithera Biosciences Inc

Cancer Prevention Pharmaceuticals Inc

Cancer Research Technology Ltd

Cantargia AB

Carna Biosciences Inc

CaroGen Corp

CBT Pharmaceuticals Inc

CCRP Therapeutics GmbH

Celgene Corp

Celldex Therapeutics Inc

Cellectar Biosciences Inc

Celleron Therapeutics Ltd

Cellestia Biotech AG

Cellix Bio Pvt Ltd

Celltrion Inc

Celyad SA

Checkmate Pharmaceuticals Inc

Chipscreen Biosciences Ltd

ChoDang Pharm Co Ltd

Chong Kun Dang Pharmaceutical Corp

Cinnagen Co

Cleveland BioLabs Inc

COARE Biotechnology Inc

Coherus BioSciences Inc

Compugen Ltd

Conatus Pharmaceuticals Inc

Corvus Pharmaceuticals Inc

Cotinga Pharmaceuticals Inc

CrystalGenomics Inc

Daiichi Sankyo Co Ltd

DanDrit Biotech A/S

Deciphera Pharmaceuticals LLC

Dr. Reddy's Laboratories Ltd

eFFECTOR Therapeutics Inc

Eisai Co Ltd

Eli Lilly and Co

Endor Nanotechnologies SL

EntreChem SL

Enzene Biosciences Ltd

Enzo Biochem Inc

EpiThany Inc

Etubics Corp

Exelixis Inc

Exicure Inc

F-star Biotechnology Ltd

F. Hoffmann-La Roche Ltd

Fate Therapeutics Inc

Formation Biologics Inc

Formosa Laboratories Inc

Forty Seven Inc

Fresenius SE & Co KGaA

Fujifilm Holdings Corporation

Fusion Antibodies Ltd

GamaMabs Pharma SA

GC Pharma

Gene Techno Science Co Ltd

Genentech Inc

Genmab A/S

Genoscience Pharma

Genzyme Corp

Gilead Sciences Inc

GlaxoSmithKline Plc

Glenmark Pharmaceuticals Ltd

Glycostem Therapeutics BV

Glycotope GmbH

Handok Inc

Hanmi Pharmaceuticals Co Ltd

Harbin Gloria Pharmaceuticals Co Ltd

Heat Biologics Inc

Heidelberg Pharma AG

Hemispherx Biopharma Inc

Hercules Pharmaceuticals BV

Humanigen Inc

Hutchison MediPharma Ltd

iDD biotech SAS

Ideaya Biosciences Inc

Idera Pharmaceuticals Inc

Ignyta Inc

Ildong Pharmaceutical Co Ltd

Immodulon Therapeutics Ltd

Immunomedics Inc

Immunovative Therapies Ltd

Incanthera Ltd

Incyte Corp

Innate Pharma SA

Innovent Biologics Inc

Inovio Pharmaceuticals Inc

Interprotein Corp

Intezyne Technologies Inc

Ipsen SA

Isofol Medical AB

Jeil Pharmaceutical Co Ltd

JHL Biotech Inc

Jiangsu Hengrui Medicine Co Ltd

Johnson & Johnson

Karyopharm Therapeutics Inc

Kazia Therapeutics Ltd

Kura Oncology Inc

Laboratorio ELEA SACIF y A

LipoMedix Pharmaceutical Inc

Loxo Oncology Inc

Luye Pharma Group Ltd

Mabion SA

mAbxience SA

MacroGenics Inc

Mantis Therapeutics BV

Marina Biotech Inc

Medesis Pharma SA

MediaPharma SRL

MediciNova Inc

MedImmune LLC

Medivir AB

MELEMA Pharma GmbH

Merck & Co Inc

Merck KGaA

Merus NV

MetaMax Ltd

Millennium Pharmaceuticals Inc

Mirati Therapeutics Inc

Moderna Therapeutics Inc

Molecular Partners AG

Molecular Templates Inc

Mologen AG

Morphotek Inc

Multimmune GmbH

Mycenax Biotech Inc

NantKwest Inc

Natco Pharma Ltd

NatureWise Biotech & Medicals Corp

Nektar Therapeutics

Neovacs SA

Nerviano Medical Sciences Srl

Nippon Kayaku Co Ltd

NormOxys Inc

Northwest Biotherapeutics Inc

Novartis AG

Noxxon Pharma AG

NuCana Plc

OBI Pharma Inc

Omnitura Therapeutics Inc

Oncology Research International Ltd

Oncolytics Biotech Inc

OncoMed Pharmaceuticals Inc

Onconova Therapeutics Inc

Ono Pharmaceutical Co Ltd

Otsuka Holdings Co Ltd

Oxford BioTherapeutics Ltd

PDS Biotechnology Corp

Pfizer Inc

Pharma Mar SA

PharmAbcine Inc

Pivotal BioSciences Inc

PlantForm Corp

Plexxikon Inc

Polaris Pharmaceuticals Inc

Precision Biologics Inc

Propanc Biopharma Inc

Protheragen Inc

Provectus Biopharmaceuticals Inc

PsiOxus Therapeutics Ltd

Puma Biotechnology Inc

Puretech Health plc

R Pharm

Rafael Pharmaceuticals Inc

RedHill Biopharma Ltd

Redx Pharma Plc

Regeneron Pharmaceuticals Inc

Rexahn Pharmaceuticals Inc

Rgenix Inc

Rhizen Pharmaceuticals SA

Richter Gedeon Nyrt

Samumed LLC

Sanofi

Scancell Holdings Plc

Seattle Genetics Inc

Second Genome Inc

Selvita SA

Shanghai Henlius Biotech Co Ltd

Siamab Therapeutics Inc

Sichuan Kelun Pharmaceutical Co Ltd

Sierra Oncology Inc

Sillajen Biotherapeutics

Simcere Pharmaceutical Group

Sino Biopharmaceutical Ltd

Sorrento Therapeutics Inc

ST Pharm Co., Ltd.

Steba Biotech SA

Sublimity Therapeutics Ltd

Sumitomo Dainippon Pharma Co Ltd

Sun Pharma Advanced Research Company Ltd

SuviCa Inc

Symphogen A/S

Syndax Pharmaceuticals Inc

SynDevRx Inc

Synermore Biologics Co Ltd

Taiho Pharmaceutical Co Ltd

TaiwanJ Pharmaceuticals Co Ltd

Takeda Pharmaceutical Co Ltd

Targovax ASA

Tarrex Biopharma Ltd

Tarveda Therapeutics Inc

Theralase Technologies Inc

Tocagen Inc

Tolero Pharmaceuticals Inc

TRACON Pharmaceuticals Inc

Trovagene Inc

United BioPharma Inc

Vaccinex Inc

VasGene Therapeutics Inc

Vaximm AG

Vincogen Corp

Vitality Biopharma Inc

WntResearch AB

Wuhan YZY Biopharma Co Ltd

XBiotech Inc

Xencor Inc

XuanZhu Pharma Co Ltd

Zelluna Immunotherapy AS

Zymeworks Inc